Impact of quadruplet therapy on PBSC mobilization/collection
Next, the impact of addition of isatuximab to RVd (six 21-day cycles) was evaluated. Mean PB CD34Addition of elotuzumab to RVd (four 21-day cycles) did not hamper PBSC collection results. Mean PB CD34